NCT00386685 - XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

January 31, 2011

Conditions

Breast Neoplasms

Interventions

DRUG

larotaxel (XRP9881)

intravenous administration

DRUG

trastuzumab

intravenous administration

Trial Locations (4)

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva